Product image of Imipenem/Cilastatin Sun (Cilastatin, Imipenem) supplied by GNH India

Imipenem/Cilastatin Sun

Active Ingredient:
Cilastatin, Imipenem
Origin:
EU

Imipenem/Cilastatin Sun (Cilastatin, Imipenem)

Imipenem, the active ingredient in Imipenem/Cilastatin Sun, is a carbapenem antibiotic presented as an intravenous injection for systemic administration. Combined with cilastatin to inhibit renal dehydropeptidase I, it provides broad‑spectrum coverage against Gram‑negative and Gram‑positive bacteria, and is used to treat serious infections in hospitalized adults and children. The drug is indicated for intra‑abdominal, urinary tract, pulmonary, skin and soft‑tissue infections, as well as septicemia, when alternative agents are unsuitable.

GNH India supplies Imipenem/Cilastatin Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Manufacturer / TM Owner

Sun Pharmaceutical Industries Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Imipenem/Cilastatin is a carbapenem antibiotic used for serious bacterial infections affecting various organ systems.
  • Complicated intra‑abdominal infections: effective bacterial eradication leading to clinical cure.
  • Complicated urinary tract infections: rapid clearance of uropathogens and symptom resolution.
  • Nosocomial pneumonia: broad‑spectrum activity that improves pulmonary infection outcomes.
  • Skin and soft tissue infections: eradicates mixed flora to promote wound healing.
  • Septicemia: systemic bacterial clearance to stabilize hemodynamics.

How It Works

  • Imipenem binds to penicillin‑binding proteins, inhibiting the final stages of bacterial cell wall synthesis, which results in cell lysis. Cilastatin co‑administered inhibits renal dehydropeptidase I, preventing enzymatic degradation of imipenem and thereby maintaining therapeutic plasma concentrations.

Side Effects

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: may be self‑limiting or indicate colitis.
  • Headache: transient and usually resolves.
  • Rash: mild skin erythema or pruritus.
  • Elevated liver enzymes: transient hepatic enzyme rise.
  • Injection site pain: local discomfort during infusion.

Serious or Rare Side Effects

  • Seizures: especially in patients with renal impairment or CNS disorders.
  • Anaphylaxis: acute hypersensitivity requiring immediate intervention.
  • Clostridioides difficile colitis: severe diarrhea with pseudomembranous colitis.
  • Thrombocytopenia: marked reduction in platelet count.
  • Renal toxicity: worsening renal function in susceptible individuals.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Use Imipenem/Cilastatin with caution in specific clinical situations.

  • Renal function: adjust dose in patients with impaired renal clearance.
  • Seizure risk: monitor patients with a history of CNS disorders.
  • Allergy: avoid in individuals with known hypersensitivity to carbapenems.
  • Pregnancy: prescribe only when the potential benefit justifies the potential risk.
  • Drug interactions: review concomitant medications for possible interactions.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Imipenem/Cilastatin may interact with other medicines; review patient medication lists.

Major Interactions (Avoid)

  • Valproic acid: may reduce serum valproate levels, risking seizure breakthrough.
  • Cisplatin: increased risk of nephrotoxicity when combined.
  • Probenecid: may raise imipenem concentrations, enhancing toxicity.

Moderate Interactions (Monitor Closely)

  • Aminoglycosides: additive nephrotoxic potential; monitor renal function.
  • Loop diuretics: may increase ototoxicity risk when used together.
  • Anticoagulants: possible enhancement of anticoagulant effect; check coagulation parameters.

Frequently Asked Questions

Imipenem/Cilastatin Sun is an intravenous carbapenem antibiotic indicated for serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, skin and soft‑tissue infections, and septicemia. It is typically reserved for patients who require broad‑spectrum coverage when other agents are unsuitable.

Imipenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, disrupting the final cross‑linking step and causing cell lysis. Cilastatin is co‑administered to block renal dehydropeptidase I, preventing rapid degradation of imipenem and ensuring adequate plasma levels for antibacterial activity.

The dosing regimen for Imipenem/Cilastatin Sun is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local antimicrobial guidelines. Healthcare professionals should refer to the product label and adjust the dose as required for each individual patient.

The safety of Imipenem/Cilastatin Sun during pregnancy and lactation has not been definitively established. It should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Imipenem/Cilastatin offers a broad spectrum of activity similar to other carbapenems such as meropenem or ertapenem, but its combination with cilastatin protects it from renal degradation, allowing higher plasma concentrations. Choice among carbapenems depends on local resistance patterns, pharmacokinetic considerations, and specific patient factors.

Imipenem/Cilastatin Sun should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and potency.

The product is supplied as a sterile powder for reconstitution and is administered intravenously. Reconstitution is performed with the appropriate diluent, and the solution is infused over the recommended period, typically 30 minutes, under aseptic conditions by qualified healthcare personnel.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and medical intervention are essential if any of these events occur.

Patients with a documented hypersensitivity to imipenem, cilastatin, or any other carbapenem should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or known drug interactions that could increase toxicity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin, Imipenem

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT